Posted by Michael Wonder on 19 Sep 2024
FDA declines to approve Vanda's marketing application for tradipitant in gastroparesis
19 September 2024 - - Vanda Pharmaceuticals today provided an update on its tradipitant development program.
On 18 September 2024, the US FDA declined to approve Vanda's new drug application of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a complete response letter.
